The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: A Randomized Controlled Trial
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of rifaximin in the secondary prevention of overt hepatic encephalopathy (HE) is well documented, but its effectiveness in preventing a first episode in patients after transjugular intrahepatic portosystemic shunt (TIPS) has not been established. OBJECTIVE: To determine whether rifaximin prevents overt HE after TIPS compared with placebo. DESIGN: Randomized, double-blind, multicenter, placebo-controlled trial. (ClinicalTrials.gov: NCT02016196). PARTICIPANTS: 197 patients with cirrhosis undergoing TIPS for intractable ascites or prevention of variceal rebleeding. INTERVENTION: Patients were randomly assigned to receive rifaximin (600 mg twice daily) or placebo, beginning 14 days before TIPS and continuing for 168 days after the procedure. MEASUREMENTS: The primary efficacy end point was incidence of overt HE within 168 days after the TIPS procedure. RESULTS: = 93) during the postprocedure period (odds ratio, 0.48 [CI, 0.27 to 0.87]). Neither the incidence of adverse events nor transplant-free survival was significantly different between the 2 groups. LIMITATIONS: The study's conclusion applies mainly to patients with alcoholic cirrhosis, who made up the study population. The potential benefit of rifaximin 6 months after TIPS and beyond remains to be investigated. CONCLUSION: In patients with cirrhosis treated with TIPS, rifaximin was well tolerated and reduced the risk for overt HE. Rifaximin should therefore be considered for prophylaxis of post-TIPS HE. PRIMARY FUNDING SOURCE: French Public Health Ministry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bureau, C., Thabut, D., Oberti, F., Dharancy, S., Carbonell, N., Bouvier, A., Mathurin, P., Otal, P., Cabarrou, P., Péron, J. M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.016 · Cited by 452 · cited 6×
“9) Mean platelet count (SD), 10(9)/L 153 (59) 155 (83) 154 (72) Mean ammonia level (SD), mmol/L 48 (22) 50 (30) 49 (26) Mean Child–Pugh score (SD)* 8 (1) 8 (1) 8 (1) Mean MELD score (SD)† 12 (4) 12 (4) 12 (4) TIPS indication: ascites, n (%) 82 (85) 78 (78) 160 (81) Mean PPG (SD), mm Hg Before TIPS 16 (4) 17 (5) 16 (5)…”
MethodSelf-citationBajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430
Kalambokis, G. N., Mouzaki, A., Rodi, M., Pappas, K., Fotopoulos, A., Xourgia, X., & Tsianos, E. V. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.025 · Cited by 130
Cited by
Kaplan, D. E., Ripoll, C., Thiele, M., Fortune, B. E., Simonetto, D. A., Garcia-Tsao, G., & Bosch, J. (2024) · Hepatology · doi:10.1097/hep.0000000000000647 · Cited by 486
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy
Montagnese, S., Rautou, P.-E., Romero-Gómez, M., Larsen, F. S., Shawcross, D. L., Thabut, D., Vilstrup, H., & Weissenborn, K. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.001 · Cited by 440
Self-citationGut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
Metadata
- Authors
- Bureau, C., Thabut, D., Jezequel, C., Archambeaud, I., D’Alteroche, L., Dharancy, S., Borentain, P., Oberti, F., Plessier, A., De Ledinghen, V., Ganne-Carrié, N., Carbonell, N., Rousseau, V., Sommet, A., Péron, J. M., & Vinel, J. P.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2021-05
- Volume
- 174
- Issue
- 5
- Pages
- 633-640
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3128019055
- Cited by
- 185
- References
- 3
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.